Sensing lead-related complications in patients with transvenous implantable cardioverter-defibrillators

Jennifer Lawton, Kenneth A. Ellenbogen, Mark A. Wood, Bruce S. Stambler, John M. Herre, Sunil Nath, Robert C. Bernstein, John P. DiMarco, David E. Haines, Szabolcs Szentpetery, Lenox D. Baker, Ralph J. Damiano

Research output: Contribution to journalArticle

Abstract

The widespread use of the redesigned Endotak™ lead (CPI, St. Paul, Minnesota), which combines transvenous pacing, sensing, and defibrillation on a single transvenous lead in patients receiving transvenous implantable cardioverter-defibrillators (ICDs), has reduced morbidity and shortened length of hospital stay after ICD implantation. We describe the incidence and management of Endotak sensing lead-related failures in a series of 348 consecutive patients from 4 institutions who underwent implantation between 1990 and 1995. We retrospectively reviewed the databases for patients receiving an ICD with an Endotak lead for the incidence of lead-related sensing abnormalities. Ten patients (2.8%) with lead-related sensing abnormalities were detected at a mean of 15 ± 11 months after ICD implantation. Sensing abnormalities were detected in 6 patients after they received inappropriate shocks. Noise or oversensing was noted in 7 patients from interrogation of the devices' data logs. Eight patients had a new transvenous sensing lead placed, 1 patient had a new Endotak lead placed, and 1 had a chronic pacemaker sensing lead converted to function as a sensing lead. No further sensing problems were noted in 8 of 10 patients during a mean follow-up of 14 ± 8 months. The site of the sensing lead failure was localized to the subrectus pocket in 5 patients and to the clavicle-first rib area in 3 patients; it was undetermined and presumed to be in the clavicle-first rib area in the other 2 patients. One patient had late failure of the defibrillation lead. We conclude that Endotak sensing lead failure does not require insertion of a new Endotak lead, but can be managed with close follow-up and insertion of a new transvenous sensing lead. Endotak lead fractures are frequently localized to the ICD pocket.

Original languageEnglish (US)
Pages (from-to)647-651
Number of pages5
JournalAmerican Journal of Cardiology
Volume78
Issue number6
StatePublished - 1996
Externally publishedYes

Fingerprint

Implantable Defibrillators
Clavicle
Lead
Ribs
Length of Stay
Incidence
Noise

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Lawton, J., Ellenbogen, K. A., Wood, M. A., Stambler, B. S., Herre, J. M., Nath, S., ... Damiano, R. J. (1996). Sensing lead-related complications in patients with transvenous implantable cardioverter-defibrillators. American Journal of Cardiology, 78(6), 647-651.

Sensing lead-related complications in patients with transvenous implantable cardioverter-defibrillators. / Lawton, Jennifer; Ellenbogen, Kenneth A.; Wood, Mark A.; Stambler, Bruce S.; Herre, John M.; Nath, Sunil; Bernstein, Robert C.; DiMarco, John P.; Haines, David E.; Szentpetery, Szabolcs; Baker, Lenox D.; Damiano, Ralph J.

In: American Journal of Cardiology, Vol. 78, No. 6, 1996, p. 647-651.

Research output: Contribution to journalArticle

Lawton, J, Ellenbogen, KA, Wood, MA, Stambler, BS, Herre, JM, Nath, S, Bernstein, RC, DiMarco, JP, Haines, DE, Szentpetery, S, Baker, LD & Damiano, RJ 1996, 'Sensing lead-related complications in patients with transvenous implantable cardioverter-defibrillators', American Journal of Cardiology, vol. 78, no. 6, pp. 647-651.
Lawton, Jennifer ; Ellenbogen, Kenneth A. ; Wood, Mark A. ; Stambler, Bruce S. ; Herre, John M. ; Nath, Sunil ; Bernstein, Robert C. ; DiMarco, John P. ; Haines, David E. ; Szentpetery, Szabolcs ; Baker, Lenox D. ; Damiano, Ralph J. / Sensing lead-related complications in patients with transvenous implantable cardioverter-defibrillators. In: American Journal of Cardiology. 1996 ; Vol. 78, No. 6. pp. 647-651.
@article{6561c62793be494ab6aea3130aff7efb,
title = "Sensing lead-related complications in patients with transvenous implantable cardioverter-defibrillators",
abstract = "The widespread use of the redesigned Endotak™ lead (CPI, St. Paul, Minnesota), which combines transvenous pacing, sensing, and defibrillation on a single transvenous lead in patients receiving transvenous implantable cardioverter-defibrillators (ICDs), has reduced morbidity and shortened length of hospital stay after ICD implantation. We describe the incidence and management of Endotak sensing lead-related failures in a series of 348 consecutive patients from 4 institutions who underwent implantation between 1990 and 1995. We retrospectively reviewed the databases for patients receiving an ICD with an Endotak lead for the incidence of lead-related sensing abnormalities. Ten patients (2.8{\%}) with lead-related sensing abnormalities were detected at a mean of 15 ± 11 months after ICD implantation. Sensing abnormalities were detected in 6 patients after they received inappropriate shocks. Noise or oversensing was noted in 7 patients from interrogation of the devices' data logs. Eight patients had a new transvenous sensing lead placed, 1 patient had a new Endotak lead placed, and 1 had a chronic pacemaker sensing lead converted to function as a sensing lead. No further sensing problems were noted in 8 of 10 patients during a mean follow-up of 14 ± 8 months. The site of the sensing lead failure was localized to the subrectus pocket in 5 patients and to the clavicle-first rib area in 3 patients; it was undetermined and presumed to be in the clavicle-first rib area in the other 2 patients. One patient had late failure of the defibrillation lead. We conclude that Endotak sensing lead failure does not require insertion of a new Endotak lead, but can be managed with close follow-up and insertion of a new transvenous sensing lead. Endotak lead fractures are frequently localized to the ICD pocket.",
author = "Jennifer Lawton and Ellenbogen, {Kenneth A.} and Wood, {Mark A.} and Stambler, {Bruce S.} and Herre, {John M.} and Sunil Nath and Bernstein, {Robert C.} and DiMarco, {John P.} and Haines, {David E.} and Szabolcs Szentpetery and Baker, {Lenox D.} and Damiano, {Ralph J.}",
year = "1996",
language = "English (US)",
volume = "78",
pages = "647--651",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Sensing lead-related complications in patients with transvenous implantable cardioverter-defibrillators

AU - Lawton, Jennifer

AU - Ellenbogen, Kenneth A.

AU - Wood, Mark A.

AU - Stambler, Bruce S.

AU - Herre, John M.

AU - Nath, Sunil

AU - Bernstein, Robert C.

AU - DiMarco, John P.

AU - Haines, David E.

AU - Szentpetery, Szabolcs

AU - Baker, Lenox D.

AU - Damiano, Ralph J.

PY - 1996

Y1 - 1996

N2 - The widespread use of the redesigned Endotak™ lead (CPI, St. Paul, Minnesota), which combines transvenous pacing, sensing, and defibrillation on a single transvenous lead in patients receiving transvenous implantable cardioverter-defibrillators (ICDs), has reduced morbidity and shortened length of hospital stay after ICD implantation. We describe the incidence and management of Endotak sensing lead-related failures in a series of 348 consecutive patients from 4 institutions who underwent implantation between 1990 and 1995. We retrospectively reviewed the databases for patients receiving an ICD with an Endotak lead for the incidence of lead-related sensing abnormalities. Ten patients (2.8%) with lead-related sensing abnormalities were detected at a mean of 15 ± 11 months after ICD implantation. Sensing abnormalities were detected in 6 patients after they received inappropriate shocks. Noise or oversensing was noted in 7 patients from interrogation of the devices' data logs. Eight patients had a new transvenous sensing lead placed, 1 patient had a new Endotak lead placed, and 1 had a chronic pacemaker sensing lead converted to function as a sensing lead. No further sensing problems were noted in 8 of 10 patients during a mean follow-up of 14 ± 8 months. The site of the sensing lead failure was localized to the subrectus pocket in 5 patients and to the clavicle-first rib area in 3 patients; it was undetermined and presumed to be in the clavicle-first rib area in the other 2 patients. One patient had late failure of the defibrillation lead. We conclude that Endotak sensing lead failure does not require insertion of a new Endotak lead, but can be managed with close follow-up and insertion of a new transvenous sensing lead. Endotak lead fractures are frequently localized to the ICD pocket.

AB - The widespread use of the redesigned Endotak™ lead (CPI, St. Paul, Minnesota), which combines transvenous pacing, sensing, and defibrillation on a single transvenous lead in patients receiving transvenous implantable cardioverter-defibrillators (ICDs), has reduced morbidity and shortened length of hospital stay after ICD implantation. We describe the incidence and management of Endotak sensing lead-related failures in a series of 348 consecutive patients from 4 institutions who underwent implantation between 1990 and 1995. We retrospectively reviewed the databases for patients receiving an ICD with an Endotak lead for the incidence of lead-related sensing abnormalities. Ten patients (2.8%) with lead-related sensing abnormalities were detected at a mean of 15 ± 11 months after ICD implantation. Sensing abnormalities were detected in 6 patients after they received inappropriate shocks. Noise or oversensing was noted in 7 patients from interrogation of the devices' data logs. Eight patients had a new transvenous sensing lead placed, 1 patient had a new Endotak lead placed, and 1 had a chronic pacemaker sensing lead converted to function as a sensing lead. No further sensing problems were noted in 8 of 10 patients during a mean follow-up of 14 ± 8 months. The site of the sensing lead failure was localized to the subrectus pocket in 5 patients and to the clavicle-first rib area in 3 patients; it was undetermined and presumed to be in the clavicle-first rib area in the other 2 patients. One patient had late failure of the defibrillation lead. We conclude that Endotak sensing lead failure does not require insertion of a new Endotak lead, but can be managed with close follow-up and insertion of a new transvenous sensing lead. Endotak lead fractures are frequently localized to the ICD pocket.

UR - http://www.scopus.com/inward/record.url?scp=10644244566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10644244566&partnerID=8YFLogxK

M3 - Article

C2 - 8831398

AN - SCOPUS:10644244566

VL - 78

SP - 647

EP - 651

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 6

ER -